Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2022-12-23 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2022-12-23 English
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
Earnings Release Classification · 95% confidence The document is a press release dated December 13, 2022, announcing 'bemoedigende eerste data' (encouraging initial data) from the ATALANTA-1 Phase 1/2 study for GLPG5101, presented at the ASH Congress. It details preliminary safety and efficacy results (ORR, CR rates, toxicity profiles) and includes quotes from the CEO and a table summarizing the presentation details. This content structure—announcing clinical trial results and key performance indicators outside of a formal quarterly/annual filing—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses specifically on presenting clinical trial data and results, it aligns best with the function of an Earnings Release (ER) which often includes operational highlights and clinical updates, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release announcing results, ER is the most fitting category among the choices, as it is an 'initial announcement of periodical financial results (key highlights only)' where clinical trial updates often substitute for traditional financial highlights in biotech/pharma. However, given the focus is purely on clinical trial data presentation at a conference, and not a standard quarterly financial report, it is a strong candidate for an Investor Presentation (IP) if it were the deck itself, or an Earnings Release (ER) if it's the accompanying press release. Since it is a formal press release announcing specific, time-sensitive data points (ORR, CR, safety), ER is often used for such announcements, even if the core content is clinical. If the document were a short notice saying 'results are attached,' it would be RPA. Since it contains the results summary itself, ER is chosen over RPA/RNS. It is not a full 10-K, IR, or MDA. Q4 2022
2022-12-13 Dutch
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
Earnings Release Classification · 95% confidence The document is a press release dated December 13, 2022, announcing encouraging initial data from a clinical study (ATALANTA-1) presented at the ASH 2022 Congress. It details efficacy and safety results (ORR of 86%, no Grade 3+ CRS/ICANS) and includes quotes from the CEO and details about the study design and future plans (topline data expected H1 2023). This content structure—announcing clinical trial results and providing company context—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since it focuses purely on clinical data presentation and not the full quarterly financial performance, it is best classified as an Earnings Release (ER) which often includes key operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the format and focus on presenting study data, it aligns most closely with the function of an Earnings Release (ER) which often incorporates major operational milestones alongside financial reporting, or in this context, a major clinical update that drives investor interest. However, since it is a press release announcing clinical data, and not a formal quarterly financial report (10-Q/10-K) or a formal earnings release document, the most appropriate category for a major, non-financial, operational announcement of this nature that is not a specific regulatory form is often the Earnings Release (ER) category, as these announcements frequently accompany or substitute for the formal earnings release structure when clinical data is the primary driver. Given the options, ER is the closest fit for a major, time-sensitive operational announcement, although RNS is a possibility if it were purely regulatory. Since it contains forward-looking statements and CEO commentary typical of earnings-related communications, ER is selected. Q4 2022
2022-12-13 English
6-K Filing
Regulatory Filings
2022-12-13 English
S-8 Filing
Regulatory Filings
2022-12-12 English
6-K Filing
Regulatory Filings
2022-11-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.